Clinical Trial Update: Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

This update covers a Phase 1b study of the EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan for HER2-low/ultra-low/null metastatic breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)
• valemetostat (valemetostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING